Sathianathen NJ, et al. - Experts determined the need for biopsy in men with an elevated prostate-specific antigen value by conducting a cost-effectiveness analysis of using Prostate Health Index (PHI), 4Kscore, SelectMDx and ExoDx Prostate IntelliScore (EPI). The quality-adjusted survival in men with an elevated PSA was improved with the use of biomarkers to determine the need for biopsy. This decreased the number of biopsies performed and treatment of indolent disease. Cost-effective strategies in this setting included obtaining a SelectMDx or EPI following an elevated PSA but before proceeding to a biopsy.